Literature DB >> 1448844

Changes in unbound and total valproic acid concentrations after replacement of carbamazepine with oxcarbazepine.

D Battino1, D Croci, T Granata, G Bernardi, G Monza.   

Abstract

Total and free valproic acid (VPA) concentrations were measured in patients switched from a combined VPA and carbamazepine (CBZ) to a combined VPA and oxcarbazepine (OXC) therapy, both administered in individualized daily doses. Four young epileptic patients (13-17 years old) were studied for a 12-week period, total and free VPA concentrations being analyzed just before and 4 h after the morning dose, at the end of VPA and CBZ therapy, and 2 and 10 weeks after CBZ was replaced by OXC. The expected increase in the level/dose (L/D) ratio of total VPA observed at the end of the study was preceded by a clear-cut increase in the L/D ratio of free VPA, which led to VPA-related side effects and required the retitration of VPA daily doses.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1448844     DOI: 10.1097/00007691-199210000-00006

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  9 in total

Review 1.  Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations.

Authors:  R Riva; F Albani; M Contin; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

Review 2.  Pharmacokinetic interactions of the new antiepileptic drugs.

Authors:  B Rambeck; U Specht; P Wolf
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

Review 3.  Clinically relevant drug interactions with antiepileptic drugs.

Authors:  Emilio Perucca
Journal:  Br J Clin Pharmacol       Date:  2006-03       Impact factor: 4.335

Review 4.  Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide.

Authors:  D Battino; M Estienne; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1995-10       Impact factor: 6.447

5.  Decreased plasma protein binding of valproate in patients with acute head trauma.

Authors:  G D Anderson; B E Gidal; R J Hendryx; A B Awan; N R Temkin; A J Wilensky; H R Winn
Journal:  Br J Clin Pharmacol       Date:  1994-06       Impact factor: 4.335

Review 6.  Place of newer antiepileptic drugs in the treatment of epilepsy.

Authors:  R Kälviäinen; T Keränen; P J Riekkinen
Journal:  Drugs       Date:  1993-12       Impact factor: 9.546

Review 7.  Clinical pharmacokinetics of oxcarbazepine.

Authors:  Theodor W May; Elisabeth Korn-Merker; Bernhard Rambeck
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 8.  Antiepileptic drugs. A review of clinically significant drug interactions.

Authors:  P N Patsalos; J S Duncan
Journal:  Drug Saf       Date:  1993-09       Impact factor: 5.606

Review 9.  Drug interactions with the newer antiepileptic drugs (AEDs)--part 1: pharmacokinetic and pharmacodynamic interactions between AEDs.

Authors:  Philip N Patsalos
Journal:  Clin Pharmacokinet       Date:  2013-11       Impact factor: 6.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.